Eiger BioPharmaceuticals, Inc.
EIGR
EIGR was delisted on the 10th of April, 2024.
47 hedge funds and large institutions have $60.4M invested in Eiger BioPharmaceuticals, Inc. in 2016 Q3 according to their latest regulatory filings, with 7 funds opening new positions, 27 increasing their positions, 3 reducing their positions, and 5 closing their positions.
800% more repeat investments, than reductions
Existing positions increased: 27 | Existing positions reduced: 3
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
40% more first-time investments, than exits
New positions opened: 7 | Existing positions closed: 5
4% more funds holding
Funds holding: 45 → 47 (+2)
6% less capital invested
Capital invested by funds: $64.3M → $60.4M (-$3.88M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
NC
Nexthera Capital
New York
|
+$4.25M |
| 2 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
+$3.79M |
| 3 |
VC
Vivo Capital
Palo Alto,
California
|
+$3.19M |
| 4 |
Wellington Management Group
Boston,
Massachusetts
|
+$3.02M |
| 5 |
BOTOTLSJU
Board of Trustees of The Leland Stanford Junior University
Redwood City,
California
|
+$1.86M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EC
EcoR1 Capital
San Francisco,
California
|
-$281K |
| 2 |
AA
Ancora Advisors
Cleveland,
Ohio
|
-$241K |
| 3 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$68.9K |
| 4 |
Citigroup
New York
|
-$7.14K |
| 5 |
Creative Planning
Overland Park,
Kansas
|
-$6.63K |
EIGR Hedge Fund Activity: Q3 2016 in Review
47 of the 3,748 institutional investors tracked by Wall St. Rank reported a position in Eiger BioPharmaceuticals, Inc. (EIGR) for Q3 2016, worth a combined $60.4M — down 6% from $64.3M a quarter earlier.
Buyers outnumbered sellers: 7 funds opened new EIGR positions and 5 closed out — a net gain of 2 holders — while 27 added to existing stakes and 3 trimmed.
The largest buyer was Nexthera Capital, adding an estimated $4.25M. The largest seller was EcoR1 Capital, exiting entirely with an estimated $281K sold.
- 47 institutional investors held Eiger BioPharmaceuticals, Inc. (EIGR) as of Q3 2016, up from 45 in Q2 2016.
- Funds reported $60.4M of Eiger BioPharmaceuticals, Inc. stock for Q3 2016, down 6% quarter-over-quarter.
- 7 funds opened new Eiger BioPharmaceuticals, Inc. positions in Q3 2016 and 5 closed out, a net change of +2 holders.
- The largest Eiger BioPharmaceuticals, Inc. buyer in Q3 2016 was Nexthera Capital, an estimated $4.25M added.
- The largest Eiger BioPharmaceuticals, Inc. seller in Q3 2016 was EcoR1 Capital, an estimated $281K sold.
Based on aggregated 13F filings for Q3 2016.